Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response-Reference-Cited by-同舟云学术

Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response

Published:2016-10-08 Issue:1 Volume:96 Page:81-85
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Cervantes Francisco, ,Correa Juan-Gonzalo,Pérez Isabel,García-Gutiérrez Valentín,Redondo Sara,Colomer Dolors,Jiménez-Velasco Antonio,Steegmann Juan-Luis,Sánchez-Guijo Fermín,Ferrer-Marín Francisca,Pereira Arturo,Osorio Santiago

Funder

Instituto de Salud Carlos III, Spanish Ministry of Health

AMPILE

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-016-2839-z.pdf

Reference21 articles.

1. Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408–2417

2. Deininger M, O’Brien SG, Guilhot F et al (2009) International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114:1126 (abstract)

3. Pfirrmann M, Baccarani M, Saussele S et al (2016) Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30:48–56

4. Hochhaus A, Saglio G, Hughes TP et al (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044–1054

5. Jabbour E, Kantarjian HM, Saglio G et al (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494–500

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression;Hematology, Transfusion and Cell Therapy;2024-07

2. Challenges in management of older patients with chronic myeloid leukemia;Leukemia & Lymphoma;2024-04-23

3. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

4. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials;Leukemia;2024-01-29

5. Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-10